Indiana University

1. Merck Sharp & Dohme Corporation $9,289,995 187 payments
2. Eli Lilly and Company $8,981,850 256 payments
3. CooperVision Inc. $6,603,957 88 payments
4. Regeneron Pharmaceuticals, Inc. $6,074,008 329 payments
5. AstraZeneca Pharmaceuticals LP $5,991,909 21 payments
6. Amgen Inc. $5,064,079 91 payments
7. Novartis Pharmaceuticals Corporation $3,871,715 40 payments
8. Abbott Laboratories $2,962,946 306 payments
9. Gilead Sciences, Inc. $2,870,448 429 payments
10. AbbVie, Inc. $2,655,520 412 payments

1. A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19 $5,100,804 8 payments
2. Phase 1/2 Fih Study of Regn5458 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) in Patients With Relapsed Or Refractory Multiple Myeloma $3,238,765 66 payments
3. STUDY NAME#A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer NSCLC with primary tumors between 1-4 cm# Big Ten Cancer Research Consortium BTCRC-LUN18-153 $2,848,032 1 payment
4. A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer NSCLC with primary tumors between 1-4 cm Big Ten Cancer Research Consortium BTCRC-LUN18-153 $2,532,794 3 payments
5. A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer NSCLC with primary tumors between 1-4 cm# Big Ten Cancer Research Consortium BTCRC-LUN18-153 $2,472,633 1 payment
6. AMG 160_Combo in Prostate Cancer_20180101 $2,004,991 14 payments
7. Phase 1/2 Fih Study of Regn5459 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) in Patients With Relapsed Or Refractory Multiple Myeloma $1,921,402 71 payments
8. Phase II Open Label Global Study to Evaluate the Effect of Dabrafenib Treatment in Children and Adolescent Subjects With Braf V600 Mutation Positive Relapsed Refractory Or Progressive HGG Tumor $1,811,673 5 payments
9. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $1,286,229 13 payments
10. An Open Label, Multi-Center Roll-Over Study to Assess Long-Term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) And/Or Mekinist (Trametinib) $1,135,506 5 payments

1. Other $7,711,424 180 payments
2. Patient care $190,351 55 payments
3. Non-patient care $41,996 7 payments
4. Overhead $9,500 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.